PGAM
APRE icon

Princeton Global Asset Management’s Aprea Therapeutics APRE Stock Holding History

Princeton Global Asset Management’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100
Closed -$669 – 682
2024
Q1 		$669 Hold
100
– – ﹤0.01% 572
2023
Q4 		$470 Hold
100
– – ﹤0.01% 623
2023
Q3 		$417 Hold
100
– – ﹤0.01% 564
2023
Q2 		$315 Hold
100
– – ﹤0.01% 566
2023
Q1 		$444 Buy
+100
New +$739 ﹤0.01% 567

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Princeton Global Asset Management's APRE Position: Q2 2024 in Review

Princeton Global Asset Management sold out of Aprea Therapeutics (APRE) in Q2 2024, closing a stake of 100 shares — an estimated $669 sold.

Princeton Global Asset Management first reported a position in APRE in Q1 2023 and held it in 5 quarters. The position peaked at $669 in Q1 2024. 28 funds tracked by Wall St. Rank hold APRE as of Q2 2024.

  • Princeton Global Asset Management reported no remaining Aprea Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Princeton Global Asset Management sold 100 Aprea Therapeutics shares in Q2 2024, an estimated $669.
  • Princeton Global Asset Management first reported a position in Aprea Therapeutics in Q1 2023 and held it in 5 quarters.
  • Princeton Global Asset Management's Aprea Therapeutics position peaked at $669 in Q1 2024.
  • 28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2024.

Based on Princeton Global Asset Management's 13F filing for Q2 2024, filed 12 Aug 2024.